

PRESS RELEASE

10 March 2025 08:00:00 CET

Saniona Appoints Pierandrea Muglia, M.D., as Chief Medical Officer

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces the appointment of Pierandrea Muglia, M.D., as Chief Medical Officer. Dr. Muglia brings more than 30 years of experience in CNS drug development and neuroscience translational research, having led numerous drug development programs from discovery to late-stage clinical trials and regulatory approvals. His experience comes from working in both large international pharmaceutical companies as in biotech, where he has successfully built new companies and supported multiple start-ups. In his new role at Saniona, Dr. Muglia will oversee and strengthen the company's clinical development and regulatory functions.

"Pierandrea's extensive expertise in clinical development is invaluable as Saniona advances its pipeline for the treatment of neurological and psychiatric diseases," said Thomas Feldthus, Chief Executive Officer of Saniona. "With our internal pipeline progressing through preclinical development and in preparations for clinical-stage development, alongside our ongoing clinical studies in collaboration with Acadia Pharmaceuticals, we are eager to leverage Pierandrea's insights and experience. His leadership will be instrumental in driving the clinical strategy, designing innovative clinical studies and strengthening our clinical development and regulatory teams."

"This is an exciting time to join Saniona as the company continues to expand its portfolio of innovative drug candidates with the potential to bring differentiated therapeutics to individuals with neurological and psychiatric disorders," said Dr. Muglia. "Having served on the Board of Directors, I have already had the opportunity to appreciate the value of Saniona's pipeline and witness the company's successes in securing international partnerships with leading pharmaceutical companies. I am enthusiastic about taking on the role of CMO and driving the development of the company's promising assets. Saniona's pipeline holds great potential and high probability of success, with strong translational plans for all molecules approaching clinical stage, that utilizing objective biomarkers to establish target engagement and demonstrate early evidence of relevant pharmacological effects in the brain will enable optimal clinical study design for in patients' trials."

Dr. Muglia is a medical doctor with clinical training in child neurology and psychiatry. He has over 30 years of experience in research and drug development, having held leadership roles at major pharmaceutical companies such as GSK and UCB, as well as management and entrepreneurial roles in biotech. Prior to his industry career, he spent ten years conducting academic research in neuropharmacology and psychiatry.

Most recently, Dr. Muglia served as Vice President and Head of Neurology Early Clinical Development at UCB, Chief Medical Officer at Handl Therapeutics, and President and Founder of GRIN Therapeutics. At GRIN Therapeutics, he successfully launched and secured funding for a clinical-stage company now entering Phase 3 trials with an innovative approach with a small molecule that targeting the underlying cause of a severe genetic neurodevelopmental disorder holds the promises to improve the multitude of symptoms that characterize the disease.

Throughout his career, Dr. Muglia has contributed to the development of molecules for a wide range of neurological and psychiatric conditions. His academic experience includes residency at the Child Psychiatry Services in the Department of Public Health, San Francisco (1996), as well as a postdoctoral fellowship as an MRC-Canada Fellow and later as Assistant Professor at the Department of Psychiatry, University of Toronto (1998-2002). He has authored over 100 publications in high-impact journals covering neuropsychopharmacology, drug development, and human genetics. He serves on scientific advisory boards for biotech companies and committees for public initiatives and patient advocacy organizations.

Dr. Muglia holds 190,000 shares in Saniona.

For more information, please contact

Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona

Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of neurological disorders. Saniona's internal pipeline includes SAN2219, targeting acute repetitive seizures; SAN2355, addressing refractory focal onset seizures; and SAN2465, positioned for major depressive disorders. Saniona has two strategic development collaborations. SAN711 is being prepared for Phase 2 for essential tremor in collaboration with Acadia Pharmaceuticals and tesofensine is out licensed for obesity to Medix, which has submitted a market authorization application (MAA) in Mexico. In addition, Saniona oversees two clinical programs poised for collaboration. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease. Saniona partners include Acadia Pharmaceuticals, Boehringer Ingelheim GmbH, Productos Medix S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market. For more information, visit www.saniona.com.

Attachments

[Saniona Appoints Pierandrea Muglia, M.D., as Chief Medical Officer](#)